A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis
Conditions
- Idiopathic Subglottic Stenosis
- Subglottic Stenosis (SGS)
Interventions
- DRUG: Pirfenidone 267 MG [Esbriet]
- DRUG: Placebo
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborators